Protocol Ledger

NCT07227870 · Phase II · RECRUITING

L19IL2/TNF in Patients With Basal Cell Carcinoma

Interventional Phase II clinical trial protocol NCT07227870 sponsored by Philogen S.p.A in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-01 Enrollment: 92 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07227870
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)92 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07227870
Protocol FieldVerified Registry Value
NCT IdentifierNCT07227870
Consolidated Lead SponsorPhilogen S.p.A
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment92 participants (ESTIMATED)
Registered Start Date2026-09-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI